Navigation Links
Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
Date:3/24/2009

Growth Will be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, and Schering-Plough, According to a New Report from Decision Resources

WALTHAM, Mass., March 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the patent expiries by 2012 of the two sales-leading therapies, new product launches will drive an increase of $4.6 billion in the overall coronary heart disease market by 2017.

The new Pharmacor report entitled Coronary Heart Disease finds that the market to treat the disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Efient/Effient, AstraZeneca's Brilinta and Schering-Plough's SCH-530348 as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.

Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 -- Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover and Pfizer's Lipitor -- the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix, Solvay's Lipanthyl and Abbott's Niaspan will also offset the negative impact of generic erosion, according to the report.

"Cardiologists' approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-myocardial infarction -- the condition that accounts for more than 70 percent of coronary heart disease market sales -- now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker," said Decision Resources Therapeutic Area Director Nikhil Mehta. "Multidrug therapy has also become routine in the treatment of stable angina. The arrival of novel agents will be welcomed by clinicians, particularly for high-risk patients, but some of these therapies could face market access and compliance hurdles."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hagerstown Cosmetic Surgeon Weathers the Current Economic Storm Despite the Sharp Decline in the Number of Cosmetic Surgeries Performed Nationwide
2. The Center for Plastic Surgery in Washington, DC Survives the Economy Despite Nationwide Data Reported by ASAPS
3. Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures
4. Georgia Metal Finisher Expands Despite Struggling Economy
5. Sexual health promotion is low among people with serious mental illnesses, despite higher risk
6. Code Pink Boot Camp Thrives Despite Rough Economy
7. State Health Reforms Progress Despite Ailing Economy
8. OrthoSynetics(TM) Same Practice New Contracts and Consults Growing Despite Economic Downturn
9. Americans Continue Eating Nutritious and Convenient Snacks Despite Tough Economic Times
10. Photos: Despite Widespread Awareness, Most Women Still Dont Feel at Risk for Cervical Cancer
11. Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- Lianluo Smart Limited (Nasdaq: LLIT ... markets and sells medical devices and wearable sleep ... and international markets, recently attended the 2016 Guangdong ... Forum, co-hosted by the Institute of Interventional Cardiology ... Provincial People,s Hospital and Cardiology Department of Guangdong ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: